MegaPro Biomedical Co., Ltd (6827.TWO)
- Previous Close
9.68 - Open
9.90 - Bid 9.46 x --
- Ask 9.70 x --
- Day's Range
9.31 - 9.90 - 52 Week Range
8.40 - 26.10 - Volume
58,764 - Avg. Volume
51,809 - Market Cap (intraday)
634.265M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.68 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.
www.megaprobio.comRecent News: 6827.TWO
View MorePerformance Overview: 6827.TWO
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6827.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6827.TWO
View MoreValuation Measures
Market Cap
640.74M
Enterprise Value
558.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
45.77k
Price/Book (mrq)
3.14
Enterprise Value/Revenue
39.91k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-2.68
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--